Levetiracetam Solution
Product Images NDC 70518-3803

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-3803). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Levetiracetam oral solution label showing 750 mg per 7.5 mL dosage strength in 10 quantity single-dose cups. The label includes the NDC number 70518-3803-00, repackaged by RemedyRepack Inc., with manufacturer information for Aurobindo, India. Storage instructions at 20-25°C are noted along with a QR code and barcode.*

FDA Label Image

Mm5 (Levetiracetam 1250mg 12.5ml 70518 3803 04)

Label for Levetiracetam oral solution, 1250 mg per 12.5 mL, in a package of 10 cups each containing 12.5 mL. The label includes directions to see the package insert, storage instructions, and repackaging information by RemedyRepack Inc. The manufacturer is listed as Aurobindo, India.*

FDA Label Image

Mm6 (Levetiracetam 1250mg 12.5ml 70518 3803 05)

Levetiracetam 1250 mg per 12.5 mL oral solution packaging label from RemedyRepack Inc. The label shows a 12.5 mL quantity, with instructions to see the package insert for directions. It includes storage temperature recommendations and states the product is repackaged by RemedyRepack Inc., Indiana, PA.*

FDA Label Image

Mm9 (Levetiracetam 1500mg 15ml 70518 3803 08)

Levetiracetam 1500 mg/15 mL oral solution packaging label from RemedyRepack Inc. The label indicates a quantity of 10 individual 15 mL cups. It includes barcodes, a QR code, manufacture details (Aurobindo, Nagar, India), and storage instructions. The label states the product is RX only and includes a caution to keep medication out of children's reach.*

FDA Label Image

Mm10 (Levetiracetam 1500mg 15ml 70518 3803 09)

Label for Levetiracetam oral solution, 100 mg/mL concentration, showing a dosage calculation of 1500 mg per 15 mL with the total quantity of 15 mL. The label includes the REMEDYREPACK INC. logo, NDC 70518-3803-09, and indicates repackaging by RemedyRepack Inc., Indiana, PA. Manufacturer listed as Aurobindo, India. Storage instructions and a barcode with a QR code are also present.*

FDA Label Image

Mm7 (Levetiracetam 2000mg 20ml 70518 3803 06)

Levetiracetam 2000 mg/20 mL oral solution label showing a quantity of 10 individual 20 mL cups. The label includes the brand name in bold, directions to see the package insert, storage instructions, and repackaging information by RemedyRepack Inc. It also displays the NDC number 70518-3803-06 and manufacturer details from Aurobindo, India.*

FDA Label Image

Mm8 (Levetiracetam 2000mg 20ml 70518 3803 07)

Label of Levetiracetam oral solution, 2000 mg per 20 mL (equivalent to 100 mg/mL) in a 20 mL quantity. The label displays the proprietary and generic name, dosage form, quantity, and repackager as RemedyRepack Inc. It includes an NDC number, manufacturing details, storage instructions, and a barcode.*

FDA Label Image

Mm3 (Levetiracetam 500mg 5ml 70518 3803 02)

Levetiracetam 500 mg/5 mL oral solution packaging label showing quantity of 10 individual 5 mL cups. Label includes the REMEDYREPACK INC. logo, barcode, and directions to see the package insert. Manufacturer is listed as Aurobindo, India. Storage instructions specify 20-25°C with allowable excursions to 15-30°C.*

FDA Label Image

Mm4 (Levetiracetam 500mg 5ml 70518 3803 03)

Levetiracetam 500 mg/5 mL oral solution label showing 5 mL quantity. The label includes RX only status, NDC 70518-3803-03, manufacturing information from Aurobindo, India, and repackaging details by RemedyRepack Inc. It includes storage instructions and a QR code.*

FDA Label Image

Mm2 (Levetiracetam 750mg 7.5ml 70518 3803 01)

Levetiracetam 750 mg / 7.5 mL oral solution label from RemedyRepack Inc. The label shows the drug name with the strength and quantity, a barcode, a QR code, and storage information. It also includes manufacturer details as Aurobindo, India, and repackager contact information.*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' showing percentages of patients achieving response with Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The graph displays responder rates of 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, indicating statistically significant differences from placebo for Levetiracetam doses.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' displaying the percentage of patients achieving a 50% or greater reduction. It compares placebo (6.3%) with Levetiracetam 1000 mg/day (20.8%) and Levetiracetam 2000 mg/day (35.2%), with indications of statistical significance versus placebo.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

A vertical bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The graph shows about 14.4% response for placebo and 39.4% response for Levetiracetam, with an asterisk indicating statistical significance for Levetiracetam versus placebo.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Bar chart illustrating responder rates (≥ 50% reduction from baseline) in Study 4, comparing placebo and Levetiracetam. The placebo group (N=97) shows a responder rate of 19.6%, while the Levetiracetam group (N=101) shows a higher responder rate of 44.6%, marked as statistically significant versus placebo.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

A bar chart titled 'Responder Rate for All Patients Ages 1 Month to <4 Years (≥ 50% Reduction from Baseline) in Study 5' comparing the percentage of patients responding to placebo and Levetiracetam. The chart shows about 19.6% for placebo (N=51) and 43.1% for Levetiracetam (N=58), with a note indicating statistical significance versus placebo.*

FDA Label Image

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

A bar chart comparing responder rates in percentage for placebo and Levetiracetam groups in a seizure study. The chart shows 45.2% for the placebo group (N=84) and 72.2% for the Levetiracetam group (N=79), indicating the proportion of patients with at least 50% reduction in seizure frequency per week in Study 7.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical structure of levetiracetam, showing its molecular arrangement including a pyrrolidone ring and side chains consistent with the active ingredient levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.